Just as the genetic landscape observed in B-cell lymphomas supports the BCR’s pathogenic role, activating translocations and mutations involving signaling intermediates downstream of the TCR are recurrently observed in PTCL, NOS. This evidence concerns the gene BCR and B-cell non-Hodgkin lymphoma.